The Future Strategy for Batch Testing of Medicinal Products in Great Britain – Outcome and Government Response The Future Strategy for Batch Testing of Medicinal Products in Great Britain – Outcome and Government Response The... The Future Strategy for Batch Testing of Medicinal Products in Great Britain – Outcome and Government Response
Proposal for Regulation of the European Parliament and of the Council on Fees and Charges Payable to EMA Adopted Proposal for Regulation of the European Parliament and of the Council on Fees and Charges Payable to EMA Adopted The... Proposal for Regulation of the European Parliament and of the Council on Fees and Charges Payable to EMA Adopted
SCHEER Final Opinion on Ibuprofen Published SCHEER Final Opinion on Ibuprofen Published The final SCHEER (Scientific Committee on Health, Environmental and Emerging Risks), Final Opinion on... SCHEER Final Opinion on Ibuprofen Published
MHRA Nitrosamines – Step 1 and 2 Submission Reminder MHRA Nitrosamines – Step 1 and 2 Submission Reminder MHRA has shared a letter which has been sent to all... MHRA Nitrosamines – Step 1 and 2 Submission Reminder
MHRA Publishes Marketing Authorisations Granted in November 2022 MHRA Publishes Marketing Authorisations Granted in November 2022 MHRA granted one licence in November 2022. Details of the marketing authorisation... MHRA Publishes Marketing Authorisations Granted in November 2022
EMA Highlights – 17th Industry Platform Meeting on Operation of EU Pharmacovigilance Legislation EMA Highlights – 17th Industry Platform Meeting on Operation of EU Pharmacovigilance Legislation The European Medicines Agency (EMA)... EMA Highlights – 17th Industry Platform Meeting on Operation of EU Pharmacovigilance Legislation
Final European Monograph on Species digestivae Final European Monograph on Species digestivae Further to its adoption by EMA Committee on Herbal Medicinal Products (HMPC) in July... Final European Monograph on Species digestivae
MHRA Publishes Marketing Authorisations Granted between 15 – 31 October 2022 MHRA’s list of marketing authorisations granted between 15 – 31 October 2022 MHRA granted two OTC licences between 15 –... MHRA Publishes Marketing Authorisations Granted between 15 – 31 October 2022
MHRA Good Manufacturing and Distribution Practice Symposia 2023 MHRA Good Manufacturing and Distribution Practice Symposia 2023 Between 21 February – 22 February 2023 MHRA is hosting the Good... MHRA Good Manufacturing and Distribution Practice Symposia 2023
Titanium Dioxide – CLP Classification – ECJ Annulment of the Classification as Carcinogenic Substance by Inhalation Titanium Dioxide – CLP Classification – ECJ Annulment of the Classification as Carcinogenic Substance by Inhalation The Court of Justice... Titanium Dioxide – CLP Classification – ECJ Annulment of the Classification as Carcinogenic Substance by Inhalation
MHRA Nitrosamines – Step 2 – Risk Assessment and Confirmatory Testing Links Updated MHRA Nitrosamines – Medicines: Marketing Authorisation Holders’ submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing updated MHRA has... MHRA Nitrosamines – Step 2 – Risk Assessment and Confirmatory Testing Links Updated
EMA Summary Report of ISG Meeting on EMA’s Extended Mandate EMA Summary Report of ISG Meeting on EMA’s Extended Mandate The European Medicines Agency (EMA) has published its summary report... EMA Summary Report of ISG Meeting on EMA’s Extended Mandate
